health Silicon Valley's Billionaire Bets on Cellular Rejuvenation Enter First Human Trial
Life Biosciences doses first patient in a landmark epigenetic reprogramming trial, as tech titans pivot from software fortunes to radical longevity science amid a backdrop of prior clinical failures.
